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Mutations in DNA2 Link Progressive Myopathy
to Mitochondrial DNA Instability
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Binghui Shen,2,* and Giacomo Pietro Comi1,6,*
Syndromes associated with multiple mtDNA deletions are due to different molecular defects that can result in a wide spectrum of
predominantly adult-onset clinical presentations, ranging from progressive external ophthalmoplegia (PEO) to multisystemic disorders
of variable severity. The autosomal-dominant form of PEO is genetically heterogeneous. Recently, causative mutations have been re-
ported in several nuclear genes that encode proteins of the mtDNA replisome machinery (POLG, POLG2, and C10orf2) or that are
involved in pathways for the synthesis of deoxyribonuclotides (ANT1 and RRM2B). Despite these findings, putative mutations remain
unknown in half of the subjects with PEO. We report the identification, by exome sequencing, of mutations in DNA2 in adult-onset
individuals with a form of mitochondrial myopathy featuring instability of muscle mtDNA. DNA2 encodes a helicase/nuclease family
member that is most likely involved in mtDNA replication, as well as in the long-patch base-excision repair (LP-BER) pathway. In vitro
biochemical analysis of purified mutant proteins revealed a severe impairment of nuclease, helicase, and ATPase activities. These results
implicate human DNA2 and the LP-BER pathway in the pathogenesis of adult-onset disorders of mtDNA maintenance.mtDNA is replicated and maintained in multiple copies
in each cell by a specific nuclear-gene-encoded set of
proteins.1 Although some members of the replication
machinery, such as the mtDNA polymerase POLG2 and
the hexameric ring-shaped helicase C10orf2 (also known
as Twinkle),3 have been identified, the roles of other
proteins thought to be relevant for mtDNA synthesis and
repair are still unclear. Inherited disorders of mtDNAmain-
tenance are associated with most deleterious mitochon-
drial diseases, which affect people of all ages. In adults,
defects in proteins involved in mtDNA replication, deoxy-
ribonucleotide metabolism, and mitochondrial fusion can
lead to the accumulation of multiple mtDNA deletions in
postmitotic tissues, such as skeletal muscle. Most affected
individuals develop progressive external ophthalmoplegia
(PEO [MIM 157640, 609283, 609286, and 610131]), which
is often accompanied by ptosis and mitochondrial myop-
athy; multisystemic involvement is not uncommon.4
Despite the discovery of causative mutations in several
genes, a firm diagnosis can be achieved, at best, in half of
patients.5 To identify genetic defects in individuals who
showed signs of mtDNA instability, we performed whole-
exome next-generation sequencing6 in a family in which
two siblings (probands 1 [P1] and 2 [P2]) developed pro-
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The Americdysfunction, as disclosed by histochemical analysis of
skeletal muscle biopsy (Figure S1, available online).
P1 is a 62-year-old male who first came to our attention
whenhewas 49 years old, whenwe diagnosed a preexisting
suspected myopathy. He had always been thin with a
harmonically decreased muscle bulk and reported that
his muscle strength had declined progressively over the
last 20 years. A neurological examination revealed an alert
person with normal cognitive function, decreased facial
expressions, moderate diffuse muscle atrophy, relatively
mild weakness with a predominant lower-limb-girdle dis-
tribution, an anserine gait with dorsolumbar hyperlor-
dosis, and a positive Gowers’ sign. At the age of 54 years,
he developed exertional dyspnea with obstructive sleep
apnea and a patent foramen ovale with minimal shunt.
Serum creatine-phosphokinase (CPK) levels were moder-
ately increased (245 IU/l; normal values are 21–195 IU/l).
Electromyography (EMG) showed neurogenic signs in
the lower-limb muscles and myogenic signs in the prox-
imal upper-limb muscles.
P2 is the 45-year-old sister of P1. During childhood, she
was easily fatigued and fell down frequently. She had
always been thin and slender and experienced cramps in
her calf muscles. She had a major depressive episode at the
age of 22 years during a postpartum period. The depressiond Transplantation, University ofMilan, Neurology Unit, Istituto Di Ricovero
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Figure 1. Molecular Findings in Muscle Tissue of Probands with
DNA2 Mutations
(A) Southern-blot analysis of muscle mtDNA derived from pro-
bands 1–4 revealed the presence of multiple bands. ‘‘C’’ indicates
control samples that display only a single band corresponding to
WT mtDNA, and ‘‘þ’’ indicates a positive control (POLG-mutated
subject).
(B) Long PCR. This panel shows an agarose-electrophoresis
separation of the WT mtDNA long-PCR amplified fragment
(approximately 8,520 bp). Variably abundant extrabands due to
mtDNA-deleted molecules from muscle DNA are observed in all
the probands, but not in age-matched controls (‘‘C’’).
(C) Quantitative PCR analysis of mtDNA content in patients’
muscle. Real-time quantitative PCR analysis was performed with
primers and probes for human MTCYB (MIM 516020, mtDNA)
and APP (MIM 104760, nDNA). Primer sequences and PCR con-
ditions are available upon request. Results were analyzed with
a Student’s t test. The mtDNA copy number was determined
by quantitative real-time PCR in skeletal-muscle samples of our
probands (P1–P4, n ¼ 4), age-matched control individuals
(n¼ 4), and three groups of individuals with autosomal-dominant
or -recessive PEO and mutations in POLG (n ¼ 4), PEO1 (n ¼ 4), or
DGUOK (n ¼ 4); no significant difference was observed. All deter-
minations were performed in triplicate. Values are normalized to
a control sample. Horizontal bars indicate mean values.remained a primary clinical problem over the following
years, and she was treated with bupropion, bromazepam,
and valproic acid. At the age of 32 years, she presented
with hyperthyroidism, which was successfully treated
with tapazole. Four years later, she had episodic obstructive
dyspnea and bronchial asthma, which were treated with
steroids. At the age of 40 years, she manifested upper-
and lower-limb-girdle muscle weakness with difficulty
climbing stairs and standing from sitting or recumbent
positions. She also complained of myalgia and muscle
cramps. Neurological examination showed mild eyelid
ptosis and ophthalmoparesis, limb-girdle muscle weak-
ness, a positive Gowers’ sign, and difficulty walking on
the tiptoes.
Written informed consent was obtained from the pro-
bands, and investigations were carried out according to
the guidelines of the Ethical Committee of Istituto Di
Ricovero e Cura a Carattere Scientifico Foundation Ca’
Granda Ospedale Maggiore Policlinico in Milan and in
agreement with Italian and European Union laws. Stan-
dard Sanger sequencing had previously ruled out the
involvement of POLG, SLC25A4 (MIM 103220), C10orf2
(also known as PEO1), POLG2 (MIM 604983), OPA1
(MIM 605290), RRM2B (MIM 604712), TK2 (MIM
188250), MFN2 (MIM 608507), and DGUOK (MIM
601465). Total DNA was extracted from muscle by means
of standard procedures. The accumulation of multiple
mtDNA deletions was confirmed by Southern-blot (Fig-
ure 1A) and long-PCR (Figure 1B) techniques, as previously
described.7 Muscle mtDNA content in our probands did
not differ from that of age-matched control individuals
or from that of groups of individuals with molecularly
confirmed forms of autosomal-dominant or -recessive
PEO (Figure 1C).
The genomic DNA of P1, P2, and an elder healthy
brother was collected, and the exome targets were captured
with the NimbleGen Sequence Capture 2.1M Human
Exome v.1.0 Array (Roche NimbleGen) and sequenced on
the GAIIx platform (Illumina). The two 82 bp paired-end
sequence reads were first trimmed of any possible B-quality
blocks from the end of the reads by removal of any pair
that had a read smaller than 36 bp. The quality scores
were then converted to the Sanger phred score with
Emboss (version 6.3.1) and aligned to the human reference
sequence GRCh37/hg19 (24 chromosomes; RefSeq acces-
sion numbers NC_000001 to NC_000024). The reference
alignment analysis was performed with CLC Genomics
Workbench v.4.7.1. The mapped reads were used for the
analysis of SNPs and deletion-insertion polymorphisms
(DIPs). The list of SNPs and DIPs was filtered with the
Phred quality scores of the position and surrounding bases.
As a result of variant calling, 14,634 SNPs were identi-
fied. These were then filtered for variants that were not
listed in dbSNP or the 1000 Genomes Project and that
were within gene regions. Of the resulting variants, 100
were shared by P1 and P2, but not by their elder healthy
brother, and 75 were nonsynonymous changes. All vari-294 The American Journal of Human Genetics 92, 293–300, Februaryants were subjected to a scan of known genes involved
in mitochondrial disorders. Seventeen nucleotide sub-
stitutions either were not confirmed by Sanger sequenc-
ing or were found in control subjects. Finally, in the
DNA2 (MIM 601810) coding sequence (RefSeq NM_
001080449.1, chromosomal region 10q21.3), we identified7, 2013
Figure 2. DNA2 Variants Occur at Con-
served Residues Located in Important
Structural Elements of Human DNA2
(A) A scheme of DNA2 includes the loca-
tion of the identified mutations in the
coding sequence. Exons are numbered.
A Diagram representing human DNA2
shows the functional domains conserved
in this enzyme.
(B) Multiple-sequence alignment of
nuclease and ATPase domains for the
DNA2 mammalian and yeast orthologous
protein sequences with the use of CLC
Bio Main Workbench v.5.1. The tabular
format of six orthologs of DNA2 sequences
is color coded to display the conservation
at each position in the alignment.
(C) Homology model of DNA2 with
ADP (blue) binding in the catalytic center
of the ATPase domain (brown) interacts
with ssDNA (pink). The positions of three
residues, Arg284, Lys313, and Val723, are
illustrated as red sticks. The nuclease and
helicase domains are displayed in purple
and cyan, respectively.the heterozygous c.851G>A mutation (exon 5), which is
predicted to result in the amino acid change p.Arg284His.
Sanger sequencing confirmed the finding in both pro-
bands (Figure 2A), whereas their healthy 64-year-old
brother did not carry this variant.
We next performed a mutational screening of DNA2 in
a cohort of undiagnosed adult subjects (n ¼ 44) with
muscle mtDNA deletions. In two additional individuals,
probands 3 (P3) and 4 (P4), we identified missense variants
c.937A>G (exon 5) and c.2167G>A (exon 12), which lead
to protein changes p.Lys313Glu and p.Val723Ile, respec-
tively. Both subjects presented with adult-onset mito-
chondrial disease that consisted of ptosis and progressive
myopathy. P3 also developed a mild weakness of the
upper- and lower-limb-girdle muscles with occasional exer-
tional dyspnea. EMG and Desmedt tests were normal, asThe American Journal of Human Gewere the levels of acetylcholine-
receptor antibodies, CPK, aldolase,
and thyroid hormones. The clinical,
histological, and molecular features
of the affected subjects with the
mutations are summarized in Table 1
and Figure S1. None of the identified
mutations were found in 460 Italian
or 180 European control chromo-
somes or by analysis of data from
>10,000 chromosomes included in
the National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing
Project Exome Variant Server.
Muscle from P1 and unaffected
controls was homogenized, and total
RNA was extracted in accordance
with the Eurozol protocol (Euro-clone). First-strand cDNA was synthesized from total
RNA with random hexamer primers with the First-Strand
cDNA Synthesis kit (GE Healthcare). The resulting RT-
PCR products were analyzed by electrophoresis and
sequenced, but there was no evidence of distinct DNA2
splicing variants.
The expression of DNA2 was quantified in eight control
human tissue samples contained in the Human Total
Master Panel II (Clontech Laboratories) by quantitative
real-time PCR analysis by means of the DDCt method
on a 7500 System (Software 2.01, Applied Biosystems).
DNA2mRNAwas evaluated with the Taqman gene-expres-
sion assay (Hs01055246_m1), and GAPDH (MIM 138400;
Hs99999905_m1) and RNA18S (Hs99999901_s1) were
used as control housekeeping genes. Real-time PCR anal-
ysis showed relatively high DNA2 mRNA levels in brain,netics 92, 293–300, February 7, 2013 295
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296 The American Journal of Human Genetics 92, 293–300, Februarycerebellum, kidney, and heart tissue, but, perhaps surpris-
ingly, a lower level of expression in skeletal muscle (Fig-
ure S2). The vulnerability of skeletal muscle toDNA2muta-
tions might be due to low expression levels, which most
likely reflects a low basal-muscle activity combined with
a high demand for mitochondrial-gene-encoded respira-
tory-chain proteins and mtDNA content. The balance
between DNA2 activity and demand for its product in
muscle is probably finely tuned and near threshold levels.
Human DNA2 is a member of the nuclease/helicase
family.8 It was recently found in mammalian mitochon-
dria, where it participates in the removal of RNA primers
during mtDNA replication;9 however, whether it is exclu-
sively localized to the mitochondria is debated.10 Human
DNA2 interacts with POLG and stimulates its catalytic
activity and most likely serves as an alternative to the
Twinkle helicase.9 As a member of the nuclease/heli-
case family, human DNA2 contains conserved nuclease,
ATPase, and helicase domains.8,11 To understand the path-
ologic role of these human DNA2 variants, we first verified
whether they are conserved in DNA2 from different
species. We found that the protein sequence alignments
revealed that the Arg284 residue is conserved in mam-
malian DNA2, whereas the Lys313 and Val723 residues
are conserved in both mammalian and yeast DNA2 (Fig-
ure 2B). We then employed the Schro¨dinger Suite 2012
Prime homology-modeling tool and three-dimensional
X-ray crystallography structures of the yeast Upf1-RNA
complex (Protein Data Bank [PDB] 2XZL) and human
Upf1 helicase-ADP complex (PDB 2GK6) as templates to
create a homolog model for the DNA2-ssDNA-ADP com-
plex (Figure 2C). This model revealed that all three
domains of human DNA2 interact with the DNA molecule
(Figure 2C). More importantly, the Arg284 and Lys313 resi-
dues are located in the nuclease domain, and the side chain
of these two residues is in direct contact with the ssDNA
molecule (Figure 2C), suggesting that p.Arg284His and
p.Lys313Glu might affect the DNA2 substrate binding
and impair its nuclease and helicase activities. On the
other hand, the Val723 residue is located in the interface
between the ATPase domain and the helicase domain
(Figure 2B), implicating that the p.Val723Ile alteration
might affect the interaction between these two domains
and the ATP-dependent helicase activity of DNA2.
To further assess the impact of the variants identified in
our probands, we transiently expressed wild-type (WT) and
recombinant forms of human DNA2 (Figure S3) as previ-
ously described.12 Nuclease activity, which is important
for efficient processing of the RNA primer intermediates
that occur in the strand-coupled replication mechanism
ofmtDNA, was assayed according to a previously described
protocol.8 In brief, WT and altered forms of human DNA2
were incubated with 0.25 pmol DNA substrate in reac-
tion buffer that contained 50 mM HEPES-KOH (pH 7.5),
4 mM MgCl2, 2 mM DTT, and 0.25 mg/ml BSA. The reac-
tions were stopped with 23 stop buffer (95% deionized
formamide, 10 mM EDTA, 0.1% bromophenol blue, and7, 2013
0.1% xylene cyanol). The nuclease products were separated
on a 15% denatured urea gel. As expected, p.Arg284His
and p.Lys313Glu, located in the nuclease domain, affected
nuclease activity; there was a complete loss of nuclease
activity for p.Arg284His and a significant reduction for
the p.Lys313Glu variant. The p.Val723Ile alteration, which
affects the helicase domain, was also associated with defec-
tive nuclease activity (30% compared to the WT protein)
(Figure 3A).
We next evaluated helicase activity, which was deter-
mined after inactivation of the nuclease domain by site-
directed mutagenesis, as described previously.12 In brief,
the reaction mixtures contained 50 mM Tris-HCl (pH
7.5), 25 mM NaCl, 2 mM DTT, 0.25 mg/ml BSA, 4 mM
MgCl2, 4 mM ATP, and 32P-labeled helicase substrate.
The substrate was prepared as described previously.13 The
30 ends of the substrate were labeled with terminal trans-
ferase (Roche). The reaction was terminated with 53 stop
solution (60 mM EDTA, 40% sucrose, 0.6% SDS, 0.25%
bromophenol blue, and 0.25% xylene cyanole FF) at the
indicated time points. The reaction was loaded on an 8%
native polyacrylamide gel.
The p.Arg284His and p.Lys313Glu altered forms of
DNA2 displayed a severe impairment in helicase activity;
DNA2 with the p.Val723Ile variant displayed enhanced
helicase activity (Figure 3B). This anomalous unbalance
in helicase activitymight be detrimental to affected tissues,
as previously demonstrated in mice in which the Twinkle
protein was overexpressed.14
These findings suggest that the activity of the nuclease
and helicase domains is likely to be coupled. Genetic
experiments performed previously on the yeast ortholog
yDna2 revealed that a mutant with helicase activity, but
not nuclease activity, was more sensitive to double-strand
breaks than a helicase- and nuclease-deficient double
mutant.15 Because both nuclease and helicase activities
rely upon an ATP-dependent mechanism, we used the
Innova Biosciences ATPase assay kit to assess the function
of ATPase in WT and altered recombinant forms of human
DNA2. The reaction mixture (20 ml) contained 30 nM puri-
fied DNA2, 40 mM Tris-HCl, 5 mM MgCl2, 25 mM NaCl,
2.5 mM DTT, 0.1 mg/ml BSA, 0.5 mM ATP, and 1 mg oligo-
nucleotide (ssDNA, 40 bases). The reaction was collected at
the indicated time points and stopped by the addition of
5 ml PiColorLock Gold mix for 5 min; the mixture was
further incubated for 30 min at room temperature after
the addition of 2 ml stabilizer. The absorbance was
measured with a NanoVue Plus spectrophotometer at
650 nm.
Biochemical analysis revealed a significant reduction of
ATPase activity in the p.Arg284His and p.Lys313Glu
altered proteins, which was expected because of the over-
lap of the nuclease and ATPase domains. No difference
was observed between the WT protein and the p.Val723Ile
altered protein (Figure 3C).
Because the human DNA2 variants were heterozygous,
we sought to determine whether they had heterozygousThe Americeffects or dominant-negative effects on its function. To
this purpose, we mixed the WT DNA2 with equal amounts
of WT, p.Arg284His, p.Lys313Glu, or p.Val723Ile forms of
the protein in order to model the situation in normal and
different mutant cells. The product of the reaction with
WT/p.Arg284His, WT/p.Lys313Glu, or WT/p.Val723Ile
proteins was approximately half of that of the reaction
with WT/WT proteins (Figures 4A and 4B), thus indicat-
ing that in this in vitro condition, WT DNA2 could not
compensate for the detrimental effect on the nuclease ac-
tivity of p.Arg284His, p.Lys313Glu, or p.Val723Ile altered
proteins.
DNA2 is critical for long-patch base-excision repair (LP-
BER), the predominant pathway for repairing small DNA
lesions induced by oxidation, alkylation, and spontaneous
hydrolysis.16 Evidence that LP-BER acts on mtDNA is sug-
gested by the mitochondrial localization of several factors,
such as flap endonuclease 1 (FEN1),17 that facilitate this
process. Together with FEN1, DNA2 is thought to be
involved in the repair of oxidative lesions in DNA mole-
cules.18 This role seems especially important for mitochon-
dria, in which there is a significant threat of oxidative DNA
damage.
Heterozygous mutations associated with autosomal-
dominant or sporadic PEO withmultiple mtDNA deletions
have been described in several genes.4 In our subject
cohort, mutations in POLG remained the major cause
of multiple-mtDNA-deletion disorders; POLG mutations
accounted for approximately 19% of all individuals pre-
senting with mitochondrial disease and were followed
by those in PEO1 (18% of our PEO and multiple-mtDNA-
deletion cohort), SLC25A4 (6.7%), and OPA1 (2.2%). We
did not detect any mutations in RRM2B, although it
appears to be relevant in other populations.19 Mutations
in DNA2 occurred in three independent probands in our
cohort. These accounted for 6.8% of genetically undiag-
nosed subjects (n¼ 44) carryingmultiplemtDNA deletions
and 3.3% of all probands (n ¼ 90) carrying multiple
mtDNA deletions as confirmed by Southern-blot and
long-PCR analyses. These results suggest that DNA2 is an
appropriate candidate for molecular screening in subjects
with sporadic or familial PEO with ascertained instability
of muscle mtDNA. Further studies of DNA2 and other
proteins involved in mtDNA-repair pathways will improve
our understanding of mtDNA replication and the clinical
consequences of its impairment.Supplemental Data
Supplemental Data include three figures and can be found with
this article online at http://www.cell.com/AJHG.Acknowledgments
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Figure 3. Changes in Enzymatic Activities of Altered Forms of DNA2
(A) Endonuclease activities of WT and altered forms of DNA2. In the top panel is the DNA double-flap substrate. WT, p.Arg284His,
p.Lys313Glu, or p.Val723Ile human DNA2 (0.8 nM) was incubated with 0.25 pmol 50 end 32P-labeled flap DNA substrate. Reactions
were carried out at 37C for 10, 20, 40, and 60 min. Arrows indicate the cleavage sites. In the bottom panel is the quantification of
DNA2 endonuclease activity. Error bars indicate SEM.
(B) Helicase activities of WT and altered forms of DNA2. In the top panel is the DNA helicase substrate. DNA2 was first altered for the
elimination of nuclease activity (p.Asp294Ala) so that helicase activity could be assayed. A helicase mixture containing 1 fmol 30-end-
labeled duplex substrate and 100 nM purified recombinant p.Asp294Ala, p.Asp294Ala/p.Arg284His, p.Asp294Ala/p.Lys313Glu, or p.As-
p294Ala/p.Val723Ile DNA2was incubated at 37C for 10, 20, 40, and 60min. In the bottom panel is the quantification of DNA2 helicase
activity. Error bars indicate SEM.
(C) ATPase activity of WT and altered forms of DNA2. ATPase activity of WT, p.Arg284His, p.Lys313Glu, or p.Val723Ile forms of human
DNA2wasmeasured with an ATPase assay kit. A reactionmixture containing 30 nM recombinant protein and 1 mg ssDNAwas incubated
at 37C for 10, 20, 40, and 60 min. In each panel, the p value was calculated by a Student’s t test. Error bars indicate SEM.
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Figure 4. Heterogeneity Effects of the Nuclease Activity of
Altered Forms of DNA2
(A) 0.2 nMWT DNA2 was mixed with 0.2 nMWTor p.Arg284His,
p.Lys313Glu, or p.Val723Ile forms of DNA2. The DNA2 mixture
was incubated with 0.25 pmol 50 end 32P-labeled flap DNA
substrates. Reactions were carried out at 37C for 10, 20, 40, and
60 min.
(B) Quantification of DNA2 cleavage products. Values aremeans5
SEM of three assays. In each panel, the p value was calculated by
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